文献速递乳腺癌

SWOG S8814试验中内分泌治疗敏感性指数与21基因乳腺癌复发评分的评估

Evaluation of the Sensitivity to Endocrine Therapy Index and 21-Gene Breast Recurrence Score in the SWOG S8814 Trial.
PubMed 文献 · J Clin Oncol · 2023-01-17

在SWOG S8814试验中,对283例接受他莫昔芬±蒽环类化疗的淋巴结阳性乳腺癌患者进行SET2,3指数的盲法回顾性验证。中位随访8.99年发生106例事件。SET2,3与RS不相关(r=-0.04),两者独立预后;SET2,3未预测化疗获益(交互P=0.77)。RS≤25且SET2,3高者5年DFS 97%,RS>25且SET2,3低者5年DFS 53%。

要点

  • SET2,3指数与21基因复发评分不相关(r=-0.04),两者独立预后。
  • SET2,3未预测蒽环类化疗获益(交互P=0.77)。
  • RS≤25且SET2,3高者5年DFS 97%,RS>25且SET2,3低者5年DFS 53%。

核心结论

  • SET2,3指数与RS不相关,显示附加预后价值,在该S8814患者亚组中未预测化疗获益。
  • SET2,3的SETER/PR和BPI组分各自为RS增加预后信息。

研究设计与样本

  • SWOG S8814试验中两个随机治疗臂的盲法回顾性临床验证,比较蒽环类化疗后他莫昔芬5年内分泌治疗与单用他莫昔芬。
  • SET2,3检测使用已测RS的肿瘤样本的全转录组RNA测序进行校准和测量,共283例患者,主要终点为无病生存期(DFS)。

主要发现

  • 中位随访8.99年,283例患者中发生106例事件。
  • SET2,3指数与RS不相关(r=-0.04),两者独立预后:SET2,3每单位HR 0.48(95%CI 0.34-0.68,P<.001);RS每10单位HR 1.28(95%CI 1.14-1.44,P<.001)。
  • SET2,3指数未预测化疗获益(交互P=0.77)。
  • RS≤25患者中93/175(53%)SET2,3高(一致低危),5年DFS 97%;RS>25患者中55/108(51%)SET2,3低(一致高危),5年DFS 53%。
  • 调整RS后,SET2,3两组分均预后:SETER/PR HR 0.65(95%CI 0.46-0.92);BPI HR 0.45(95%CI 0.31-0.64)。

局限性

  • 比例风险假设仅在前5年满足。
  • 原文未报告其他局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

PURPOSE: Chemotherapy has not demonstrated benefit over adjuvant endocrine therapy alone for postmenopausal patients with node-positive breast cancer with a 21-gene breast recurrence score (RS) of 25 or below (RS ≤ 25). We tested whether combined results from RS and the sensitivity to endocrine therapy (SET2,3) index of endocrine-related transcription (SETER/PR) adjusted for baseline prognostic index (BPI) improve prognostic assessment, and whether SET2,3 predicted benefit from anthracycline-based chemotherapy. METHODS: A blinded retrospective clinical validation of SET2,3 in two randomized treatment arms from the SWOG S8814 trial comparing adjuvant anthracycline-based chemotherapy followed by tamoxifen endocrine therapy for 5 years, versus tamoxifen alone. SET2,3 assay was calibrated and measured using whole-transcriptome RNA sequence of tumor samples already tested for RS. The primary end point was disease-free survival (DFS). RESULTS: There were 106 events in 283 patients over a median follow-up of 8.99 years. Proportional hazards assumptions were met during the first 5 years only. SET2,3 index and RS were not correlated (r = -0.04) and were independently prognostic (SET2,3: hazard ratio [HR], 0.48 per unit; 95% CI, 0.34 to 0.68; P < .001; RS: HR, 1.28 per 10 units; 95% CI, 1.14 to 1.44; P < .001). SET2,3 index did not predict chemotherapy benefit (interaction P = .77). SET2,3 was high in 93/175 (53%) patients with RS ≤ 25 (concordant low-risk), with 5-year DFS 97%. SET2,3 was low in 55/108 (51%) patients with RS > 25 (concordant high-risk), with 5-year DFS 53%. Both components of SET2,3 index were prognostic after adjustment for RS: SETER/PR (HR, 0.65; 95% CI, 0.46 to 0.92) and BPI (HR, 0.45; 95% CI, 0.31 to 0.64). CONCLUSION: SET2,3 index was not correlated with RS, demonstrated additive prognostic performance, and was not chemopredictive in this subset of patients from S8814. The SETER/PR and BPI components of SET2,3 each added prognostic information to RS.

来源:J Clin Oncol,查看原文。版权归原作者所有。

引用

  1. Speers CW, Symmans WF, Barlow WE, et al. Evaluation of the Sensitivity to Endocrine Therapy Index and 21-Gene Breast Recurrence Score in the SWOG S8814 Trial. J Clin Oncol. 2023. PMID: 36649570. doi:10.1200/JCO.22.01499

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。